Study:
A Phase II Trial of Induction Chemotherapy With Epirubicin, Oxaliplatin and Fluorouracil (EOF) Followed by Esophagogastrectomy and Post-operative Concurrent Chemoradiotherapy With Fluorouracil and Cisplatin, in Patients With Loco-regionally Advanced Adenocarcinoma of the Esophagus, Gastroesophageal Junction and Gastric Cardia
Rationale:
Drugs used in chemotherapy, such as epirubicin, oxaliplatin, fluorouracil, and
cisplatin, work in different ways to stop the growth of tumor cells, either by killing the
cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill
tumor cells. Giving chemotherapy before surgery may make the tumor smaller and reduce the
amount of normal tissue that needs to be removed. Giving chemotherapy and radiation therapy
after surgery may kill any tumor cells that remain after surgery.
Purpose:
This phase II trial is studying how well giving combination chemotherapy, surgery,
and radiation therapy works in treating patients with locoregionally advanced cancer of the
esophagus, gastroesophageal junction, or stomach.
Study Status: Active, not recruiting
Recruiting:
n/a
| Condition |
Intervention |
Phase |
Esophageal Cancer
Gastric Cancer |
Drug: cisplatin
Drug: epirubicin hydrochloride
Drug: fluorouracil
Drug: oxaliplatin
Procedure: adjuvant therapy
Procedure: neoadjuvant therapy |
Phase 2 |
Verified by
Case Comprehensive Cancer Center
November, 2012
Sponsored by: Case Comprehensive Cancer Center
Information provided by: Case Comprehensive Cancer Center
ClinicalTrials.gov identifier: NCT00601705
Study Type: Interventional
Study Design: Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
Cleveland, Ohio 44106-5065
United States
David J. Adelstein, MD., Principal Investigator